Pacific Therapeutics Increases Private Placement

ID: 1463467
recent pressrelease next pressrelease

(businesspress24) - Pacific Therapeutics Increases Private Placement

VANCOUVER, BC, Canada - October 13, 2016 - Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (Frankfurt: A2AFT9) (the Company) announces changes to the previously announced (August 2, 2016) private placement in connection with its proposed transaction (the Transaction) with Tower Three SAS (the T3), a South American. The company will be increases the minimum raise from $750,000 to $1,500,00 and increases the maximum to $2,250,000 at an intended price of $0.15 per Unit.

Private Placement Financing

Concurrent Financing

The Transaction is subject to PT completing an equity financing (the Concurrent Financing) by way of a private placement of units (the Units) to raise a minimum $1,500,000 and up to a maximum $2,250,000 at an intended price of $0.15 per Unit. Each Unit will consist of one common share and one common share purchase warrant. Each full warrant will entitle the holder to purchase an additional common share at the price of $0.40 per share for a period of twelve months from the closing of the Transaction. Should the Companys share price trade at $0.60 per share for 10 consecutive trading days then the Company will have the option to give notice to the warrant holders to accelerate the exercise of the warrants within 10 days or the warrants will expire. The parties acknowledge that the funds from the Concurrent Financing will be held in escrow and not released until the Canadian Securities Exchange (CSE) approves the Transaction on such terms to be more particularly described in the Definitive Agreement (hereinafter defined). The Company may pay finder fees in connection with the Concurrent Financing.

The net proceeds from the Concurrent Financing will be used for the development of the business and general working capital purposes.

Further details about the Transaction and the combined entity will be provided in a comprehensive press release if and when the parties enter into a definitive agreement. The Transaction, if completed, will constitute a fundamental change pursuant to Canadian Securities Exchange (CSE) policies.

Completion of the Transaction is subject to a number of conditions, including but not limited to acceptance by the CSE. There can be no assurance that the Transaction will be completed as proposed or at all.

About Tower Three SAS

Tower Three SAS is a privately held limited liability company formed under the laws of the Republic of Columbia. Tower Three SAS was founded in 2015 with a mission to own and operate high-quality cellular network infrastructure sites in South American markets that are experiencing strong usage growth.

Tower Three SAS focuses primarily on building towers in municipalities where there is limited or no cellular coverage. This enhances the probability of multiple carriers sharing the tower and minimizes competitive risk. Tower Three SAS has assembled a decorated management team with top-tier cellular development experience with one of South America''s largest tower developers. Tower Three SAS is currently focused on 4G LTE infrastructure expansion in Columbia and will look to open other territories.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the U.S. Securities Act), or any state securities law and may not be offered or sold in the United States, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

For further information, please contact:
Robert Nick Horsley, CEO & Director
(604) 559-8051

Certain statements included in this press release constitute forward-looking information or statements (collectively, forward-looking statements), including those identified by the expressions anticipate, believe, plan, estimate, expect, intend, may, should and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Trading in the securities of the Company should be considered highly speculative.

All information in this press release concerning T3 has been provided for inclusion herein by T3. Although the Company has no knowledge that would indicate that any information contained herein concerning T3 is untrue or incomplete, the Company assumes no responsibility for the accuracy or completeness of any such information.

Statements about the execution of a Definitive Agreement, closing of the Transaction, expected terms of the Transaction, the number of securities of the Company that may be issued in connection with the Transaction, the ownership of the Company, and the parties ability to satisfy any and all other closing conditions, and receive necessary regulatory and CSE approvals in connection therewith, are all forward-looking information. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management''s reasonable assumptions, there can be no assurance that the Transaction will occur or that, if the Transaction does occur, it will be completed on the terms described above. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Companys forward-looking statements.

More information: http:// http:// http:// http://

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: irw
print pressrelease  send to a friend  

Date: 10/13/2016 - 05:00
Language: English
News-ID 1463467
Character count: 3615
Firma: Pacific Therapeutics Ltd.
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Wien


Number of hits: 152


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 406
Register today: 1
Register yesterday: 0
Members online: 0
Guests online: 48

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.